Topotecan for the treatment of small-cell lung cancer

References

• Wu AH, Henderson BE, Thomas DC, Mack TM. Secular trends in histlogic types of lung cancer. J. Natl Cancer Inst.77, 53–56 (1986).
   PubMedGoogle Scholar
• Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission. Prophylactic cranial Irradiation Overview Collaborative Group. N. Engl. J. Med.341, 476–484 (1999).
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Papadakis E, Veslemes M et al. A multicentre randomised clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first line treatment in patients with small cell lung cancer. Ann. Oncol.12(4), 463–470 (2001).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Macha HN et al. Randomised Phase III trial of paclitaxel, etoposide and carboplatin versus carboplatin, etoposide and vincristine in patients with small cell lung cancer. J. Natl Cancer Inst.95(15), 1118–1127 (2003).
   PubMedGoogle Scholar
• Niell HB, Herndon JE 2nd, Miller AA et al. Randomised Phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive stage small cell lung cancer. Cancer and Leukaemia Group B Trial 9732. J. Clin. Oncol.23(16), 3752–3759 (2005).
   PubMed Web of Science ®Google Scholar
• Lowenbraun S, Bartolucci A, Smalley RV, Lynn M, Krauss S, Durant JR. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung cancer. Cancer44, 406–413 (1979).
   PubMed Web of Science ®Google Scholar
• Smith IE, Evans BD. Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. Cancer Treat. Rev.12(Suppl. A), 73–75 (1985).
   Google Scholar
• Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin. Oncol.15, 278–299 (1988).
   PubMed Web of Science ®Google Scholar
• Einhorn LH. Initial therapy with cisplatin plus VP-16 in small cell lung cancer. Semin. Oncol.13, 5–9 (1986).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Hansen HH, Hansen M et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small cell lung cancer. J. Clin. Oncol.5, 585–591 (1987).
   PubMed Web of Science ®Google Scholar
• Sundstrom S, Bremner RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimens in small cell lung cancer: results from a randomised Phase III trial with 5 years follow up. J. Clin. Oncol.20(24), 4665–4672 (2002).
   PubMed Web of Science ®Google Scholar
• Yau T, Ashley S, Popat S et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age ≥70 years) with small cell lung cancer. Br. J. Cancer94(1), 18–21 (2006).
   Google Scholar
• Ardizzoni A, Tjan-Heijnen VC, Postmus PE et al. Standard versus intensified chemotherapy with granulocyte colony stimulating factor support in small cell lung cancer : a prospective European Organisation for research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J. Clin. Oncol.20, 3947–3955 (2002).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Qian W Girling DJ et al. Ifosphamide, carboplatin and etoposide with mid cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer and good performance status (PS): results of an MRC randomised trial (LU21). Proc. Am. Soc. Clin. Oncol.23(33), 8371–8379 (2005).
   PubMedGoogle Scholar
• Banaji U, Ashley S, Coward J et al. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer54, 371–377 (2006).
   Google Scholar
• Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist9(6), 4–13 (2004).
   PubMed Web of Science ®Google Scholar
• Thatcher N, Eckhardt J, Green M. Options for 1st and 2nd line therapy in small cell lung cancer – a workshop discussion. Lung Cancer41(4), S37–S41 (2003).
   Google Scholar
• Than C, Khuri F. The Eckardt article reviewed. Oncology17, 206–208 (2003).
   Google Scholar
• Depierre A, von Pawel J, Hans K et al. Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer: a multicentre Phase III study. Lung Cancer18, 35 (1997) (Abstract 126).
   Google Scholar
• Eckardt J, Gralla R, Piamer MC et al. Topotecan (T) as 2nd line therapy in patients with small cell lung cancer: a Phase II study. Ann. Oncol.7, 107 (1996) (Abstract 513).
   Google Scholar
• Ardizzoni A, Hansen H, Dombernowski P et al. Topotecan a new active drug in 2nd line treatment of small cell lung cancer: a Phase II study in patients with refractory and sensitive disease. J. Clin. Oncol.15, 2090–2096 (1997).
   PubMed Web of Science ®Google Scholar
• Eckhardt J, Depierre A, Ardizzoni A et al. Pooled analysis of topotecan (T) in the second line treatment of patients (pts) with sensitive small cell lung cancer. Proc. Am. Soc. Clin. Oncol.16, 1624 (1997).
   Google Scholar
• von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J. Clin. Oncol.17(2), 658–667 (1999).
   PubMed Web of Science ®Google Scholar
• Korfel A, Oehm C, von Pawel J et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre Phase II study. Eur. J. Cancer38, 1724–1729 (2002).
   PubMed Web of Science ®Google Scholar
• Garst J, Buller R, Lane S, Crawford J. Topotecan in the treatment of elderly patients with relapsed small cell lung cancer. Clin Lung Cancer,7(3), 190–196 (2005).
   Google Scholar
• Treat J, Huang CH, Lane SR, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist9(2), 173–181 (2004).
   PubMed Web of Science ®Google Scholar
• Greco FA, Burris HA, Yardley DA et al. Phase II trial of weekly topotecan in the second line treatment of SCLC. Lung Cancer41(2), 237 (2003).
   PubMedGoogle Scholar
• Stathopoulos GP, Christodoulou CH, Stathopoulos J et al. Second line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a Phase II study. Cancer Chemother. Pharmcol.57(6), 796–800 (2006).
   PubMed Web of Science ®Google Scholar
• Schellens JH, Creemers GJ, Beijnen JH et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer73, 1268–1271 (1996).
   PubMed Web of Science ®Google Scholar
• Gerrits CJH, Burris H, Schellens JMH et al. 5 days of once daily oral topotecan, a Phase I and pharmacologic study in adults. Ann. Oncol.,7(Suppl. 5), 5970 (1996).
   Google Scholar
• von Pawel J, Gatzemeier U, Pujol JL et al. A Phase II comparator oral versus intravenous topotecan. J. Clin. Oncol.19(6), 1743–1749 (2001).
   PubMed Web of Science ®Google Scholar
• Eckardt JR, Von Pawel J, Hainsworth JD et al. Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international Phase III study. Proc. Am. Soc. Clin. Oncol.22, 619 (2003) (Abstract 2488).
   Google Scholar
• O’Brien MER, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small cell lung cancer. J. Clin. Oncol.24(34), 5441–5447 (2006).
   PubMed Web of Science ®Google Scholar
• Jonsson E, Fridberg H, Nygren P et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumour cells from patients. Eur. J. Clin. Pharmacol.54, 509–514 (1998).
   Google Scholar
• Ardizzoni A, Manegold C, Dabruyne C et al. EORTC 08957 Phase II study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer. Clin. Cancer Res.9, 143–150 (2003).
   PubMed Web of Science ®Google Scholar
• Jeh JR, Geoffrey FJ, Rowland KM et al. Topotecan (T) and paclitaxel (P) in previously treated patients with refractory or relapsed small cell lung cancer: a Phase II trial of the North Central Cancer Treatment Group. Proc. Am. Soc. Clin. Oncol.667, 22 (2003).
   Google Scholar
• Jordan C, Friess G, Page RD. Topotecan and vincristine as second line combination treatment of small cell lung cancer after failed first line therapy with carboplatin and etoposide. Proc. Am. Soc. Clin. Oncol.22, 680 (2003).
   Google Scholar
• Aisner J, Musanti R, Beers S et al. Sequencing topotecan and etoposide plus etoposide to overcome topo I and II resistance: a pharmacodynamically based Phase I trial. Clin. Cancer Res.9, 2504–2509 (2003).
   PubMed Web of Science ®Google Scholar
• Quoix E, Breton JL, Gervais R et al: A randomised Phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer49, 253–261 (2005).
   Google Scholar
• Schiller JH, Adak S, Cella D et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 – a Phase III trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.19, 2114–2122 (2001).
   PubMed Web of Science ®Google Scholar
• Miller AA, Hargis JB, Lilenbaum RC et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumours: a Cancer and Leukaemia Group B study. J. Clin. Oncol.22, 7046 (2004).
   Google Scholar
• Stewart D. Topotecan in the first line treatment of small cell lung cancer. Oncologist9(Suppl. 6), 33–42 (2004).
   Google Scholar
• Hainsworth JD, Morrissey LH, Scullin DC Jr et al. Paclitaxel, carboplatin and topotecan in the treatment of patients with small cell lung carcinoma: a Minnie Pearl Cancer Research Network. Cancer94, 2426–2433 (2002).
   Google Scholar